ArticleAnnals of medicine and surgery (2012)2026
Zoledronic acid in the treatment of severe scoliosis associated with neurofibromatosis type 1 (NF1): a case report.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: We report the first case of perioperative zoledronic acid administration in an adolescent with neurofibromatosis type 1 (NF1) complicated by severe scoliosis. This case provides a hypothesis-generating experience for bone turnover screening and bisphosphonate intervention in the management of NF1-related scoliosis. Presentation of case: First case report: adolescent NF1 with severe scoliosis treated by perioperative zoledronic acid plus halo-pelvic traction and spinal fusion. The regimen included preoperative daily traction and 4 mg zoledronic acid, followed by postoperative spinal fusion and 1 mg zoledronic acid. Traction improved spinal alignment and pulmonary function. Bone turnover markers decreased after zoledronic acid administration. Clinical discussion: For the first time, zoledronic acid was administered perioperatively during primary spinal fusion in an adolescent patient with NF1. Bone turnover markers were reduced after zoledronic acid administration, and a temporal decrease in bone turnover was observed during traction and after surgery. The combination of traction and zoledronic acid was associated with favorable bone marker changes in this patient. A preliminary, hypothesis-generating bone management algorithm is proposed based on this single case: screen for bone markers and spinal CT in patients with severe NF1-associated scoliosis; if high bone turnover or low CT values are detected, consider zoledronic acid administration prior to traction. Conclusion: In this adolescent patient with NF1-associated severe scoliosis, perioperative zoledronic acid combined with traction and spinal fusion was associated with reduced bone turnover markers and stable implant fixation at a 12-month follow-up. This strategy may provide a hypothesis-generating option for perioperative bone health management. Further large, controlled studies are needed to confirm its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.